These systems are multifaceted issues that include, inter alia, pharmacology, protein research, and chemical modifications of macromolecules. In conclusion, cellulose, which is a non-biodegradable chain glucose polymer, can be successfully used as a drug carrier, which opens up new research perspectives.ĭrug carrier systems have been developed for approximately 70 years, although this idea was proposed more than 100 years ago by Ehrlich.
#Malvern zetasizer software 7.11 free
In the in vivo experiment to treat orthotopically implanted mammary tumours, the conjugate and the free drug, both applied intravenously, showed maximum inhibition of tumour growth of 48.4% and 11.2%, respectively. The conjugate showed 10-fold lower cytotoxicity to the 4 T1 mammary tumour cell line than the free drug. The conjugate showed the lowest stability (half-life 154 h) in plasma. The degradation of the conjugate in phosphate buffer and plasma followed first-order kinetics. Dynamic light scattering analysis showed an increase in the polydispersity of the conjugate. Gel filtration HPLC analysis showed that the conjugate contained approximately 2% free drug. A conjugate containing on average 9.5 molecules of MTX per molecule of cellulose was developed. Methotrexate was linked to cellulose by methyl ester bonds. Hydroxyethylcellulose, with a molecular weight of 90 kDa and soluble in water, was used. The present study aimed to verify the suitability of cellulose as a carrier for methotrexate (MTX).
Drug carriers are various nano- and macromolecules, e.g., oligosaccharides, proteins, and liposomes. Clinical and experimental cancer therapy is multifaceted one such facet is the use of drug carriers.